Surgery should be considered earlier as a front-line option, not a last resort.
In the long human struggle against heart disease, a Mayo Clinic study quietly reframes a familiar debate — not as a contest between surgery and medication, but as a question of fit between patient and tool. Tracking over 800 adults with obesity, researchers found that bariatric surgery reduced lifetime cardiovascular risk by 8.6 percentage points compared to 1.7 for GLP-1 drugs, a gap explained largely by the depth and durability of weight loss each approach achieves. The finding does not declare a winner so much as it asks medicine to reconsider its habits — specifically, the reflex to treat surgery as a last resort rather than an early, legitimate option for those who stand to benefit most.
- Surgery cut lifetime heart disease risk more than five times as much as GLP-1 medications — 8.6 versus 1.7 percentage points — a gap too large for clinical practice to quietly absorb.
- The weight-loss difference drives the divide: surgery patients shed an average of 28% of body weight while medication patients lost 11%, and every additional pound lost translated into measurable cardiac protection.
- A cultural tension surfaces in the data — surgery has long been treated as medicine's reluctant last resort, but these findings pressure that assumption, suggesting earlier surgical intervention could prevent years of accumulating cardiovascular risk.
- Researchers are careful not to pit the two treatments against each other, framing surgery and GLP-1 drugs as complementary instruments rather than rivals, each suited to different patients, circumstances, and goals.
- The study lands as an invitation to individualize: the right treatment is the one most likely to produce the best long-term outcome for a specific person, not the one that fits the most familiar clinical script.
A Mayo Clinic study published in Annals of Surgery has delivered the most direct head-to-head comparison yet between bariatric surgery and GLP-1 weight-loss medications — and the results complicate the comfortable assumption that the two are roughly interchangeable.
The research followed 812 adults with obesity, 579 of whom underwent metabolic and bariatric surgery and 233 of whom took GLP-1 medications. The central question was not simply how much weight each group lost, but how much each treatment reduced lifetime cardiovascular risk — the probability of suffering a heart attack, stroke, or related event over the years ahead. Surgery reduced that risk by 8.6 percentage points. Medications reduced it by 1.7. The gap was driven largely by weight loss: surgical patients lost an average of 28% of their body weight, while those on medications lost around 11%, and the relationship between greater weight loss and greater cardiac protection was consistent and clear.
Lead researcher Wissam Ghusn acknowledged both treatments work, but noted that surgery's advantage appears tied to the permanence of its effects — where medications require ongoing use to sustain results, surgery creates lasting anatomical change. Metabolic surgeon Omar Ghanem was careful to resist framing the findings as a verdict. The real message, he argued, is that obesity treatment should be understood as a strategy for reducing cardiovascular risk, not merely for shrinking a number on a scale.
What the study ultimately challenges is the clinical habit of positioning surgery as a last resort. The data suggest it deserves a place at the table earlier — as a front-line option for patients who are good candidates and whose long-term health would benefit most from deeper, more durable weight loss. Rather than competing, surgery and medication emerge from this research as complementary tools, each with a distinct profile of benefit, waiting to be matched thoughtfully to the person in front of the doctor.
Researchers at Mayo Clinic have completed the most direct comparison yet between two of the most talked-about obesity treatments: surgery and the newer GLP-1 medications that have captured public attention over the past few years. The findings, published in Annals of Surgery, show both approaches work. But surgery delivers something the drugs do not: a substantially larger reduction in the long-term risk of heart disease.
The study tracked 812 adults with obesity. Of these, 579 underwent metabolic and bariatric surgery—procedures that physically alter the digestive system to reduce food intake and absorption. The remaining 233 took GLP-1 medications, the class of drugs that includes the widely publicized weight-loss injectables. Over the follow-up period, researchers measured how each treatment affected lifetime cardiovascular risk, the probability that a person will suffer a heart attack, stroke, or related event over their remaining years.
The difference was striking. Surgery reduced lifetime cardiovascular risk by 8.6 percentage points. The medications reduced it by 1.7 percentage points. Weight loss told much of the story: patients who had surgery lost an average of 28 percent of their body weight, while those on medications lost about 11 percent. And there was a clear relationship between how much weight someone shed and how much their heart disease risk fell, particularly for those who lost more than a fifth of their body weight after surgery.
Wissam Ghusn, the Mayo researcher who led the study, framed the finding carefully. "Both treatments are effective," he said, "but surgery appears to provide a greater reduction in long-term cardiovascular risk, especially when it leads to larger and more sustained weight loss." The emphasis on sustained weight loss matters. Medications work while people take them; surgery creates a permanent anatomical change. That durability may explain why the cardiovascular benefit persists longer.
Omar Ghanem, a metabolic surgeon and chair of the relevant division at Mayo, pushed back against the idea that the study was meant to crown a winner. "This study reinforces that obesity treatment should be viewed as a strategy to reduce cardiovascular risk, not just body weight," he said. The real insight, he suggested, is that doctors and patients should think about obesity treatment the way they think about any serious health condition: by choosing the tool most likely to produce the best long-term outcome for that specific person. For some, that might be surgery. For others, medications might be the right fit—perhaps because of age, other health conditions, or personal preference.
The findings could shift how obesity treatment is discussed in clinical practice. Surgery has traditionally been presented as a last resort, something you consider only after diet and exercise have failed and medications have been tried. The Mayo data suggest a different framework: surgery should be on the table earlier, as a legitimate first-line option for patients who are good candidates and whose long-term health goals would benefit most from the larger weight loss and cardiovascular protection it offers.
Ghanem offered a final thought that captures the study's real message: "Rather than thinking of these treatments as competing options, we should view them as complementary tools. Both surgery and medications play important roles in reducing long-term cardiovascular risk, and the right approach depends on the individual patient." The study does not settle which treatment is better. It clarifies what each one can do, and invites a more honest conversation about which one might do the most good for whom.
Notable Quotes
Both treatments are effective, but surgery appears to provide a greater reduction in long-term cardiovascular risk, especially when it leads to larger and more sustained weight loss.— Wissam Ghusn, M.D., Mayo Clinic researcher
Rather than thinking of these treatments as competing options, we should view them as complementary tools. Both surgery and medications play important roles in reducing long-term cardiovascular risk, and the right approach depends on the individual patient.— Omar Ghanem, M.D., metabolic surgeon at Mayo Clinic
The Hearth Conversation Another angle on the story
Why does weight loss matter so much for heart disease risk? Isn't the benefit mostly about being lighter?
Weight loss is the mechanism, but it's not just about the number on the scale. When you lose significant weight, especially 20 percent or more, you're reducing the metabolic stress on your heart, improving blood pressure, cholesterol, and blood sugar control. Surgery achieves that more dramatically and durably than medications.
So the study is saying surgery is better?
Not exactly. It's saying surgery produces a bigger cardiovascular benefit because it produces bigger, more sustained weight loss. But that doesn't mean it's right for everyone. Surgery is invasive, carries real risks, and requires permanent lifestyle changes. Medications are easier to start and stop.
Then why would anyone choose surgery if medications are simpler?
Because the long-term payoff is larger. If you're 45 and facing decades of heart disease risk, the 8.6 percent reduction from surgery might add years to your life. If you're older or have other health issues, the medication route might make more sense.
The study mentions these should be complementary tools. What does that actually mean in practice?
It means a doctor shouldn't automatically say "try the drug first, surgery later." Instead, they should ask: What are this patient's long-term health goals? How much weight loss do they need? How long do they need the benefit to last? Then pick the tool—or combination of tools—that answers those questions best.
Could someone use both?
Theoretically, yes. Someone might have surgery and still take medications for other reasons, or medications might help someone maintain weight loss after surgery. The study doesn't explore that, but it opens the door to thinking about them as parts of a larger strategy rather than either-or choices.